Last updated: March 17, 2026
Case Overview
Peluso v. Shire U.S., Inc. involves a legal dispute filed under docket number 2:15-cv-07225 in the U.S. District Court for the Central District of California. The case centers on allegations of product liability, misrepresentation, and breach of warranty concerning Shire's pharmaceutical product.
Case Background
Plaintiff, Peluso, claims to have experienced adverse effects allegedly caused by Shire’s medication, which is approved for treatment of specific disorders. The allegations include that Shire:
- Failed to provide adequate warnings regarding potential side effects.
- Made misrepresentations about the safety profile of the drug.
- Breached statutory and contractual warranties.
The complaint was filed in 2015, with subsequent amendments addressing defendant's responses and additional factual allegations.
Legal Issues
Key legal questions involve:
- Whether Shire's labeling and warnings were sufficient under FDA regulations.
- If the company committed misrepresentation by omitting material information.
- Whether the manufacturer breached warranties of merchantability or fitness for a particular purpose.
- The applicability of federal preemption under the Food, Drug, and Cosmetic Act (FDCA).
Major Procedural Milestones
- Initial Complaint (2015): Filed alleging product liability and misrepresentation.
- Motion to Dismiss (2016): Shire moved to dismiss based on preemption arguments and failure to state a claim.
- Remanded and Discovery (2017-2019): Plaintiff pursued discovery, challenging the adequacy of warning labels.
- Summary Judgment Motions (2020): Both parties filed motions, with the court granting some in favor of Shire concerning federal preemption.
- Trial and Post-Trial Motions (2021): The case was resolved via summary judgment on various claims, with residual issues addressed through appeals.
Court’s Ruling and Rationale
In 2021, the district court granted Shire’s motion for summary judgment on federal preemption grounds, citing the consistent FDA-approved labeling as a defense. The court found that:
- Federal law preempts state-level claims that conflict with FDA-approved labeling.
- The plaintiff failed to establish a duty of disclosure beyond federally mandated warnings.
- State claims of misrepresentation and breach of warranty could not stand where federal approval preempts such assertions.
The court dismissed the remaining claims with prejudice, effectively ending the litigation at the trial level.
Litigation Impact Analysis
- Preemption Defense: The case underscores the strong influence of federal preemption in pharmaceutical liability lawsuits, especially when labels are FDA-approved.
- Warning Label Litigation: Shows courts’ reliance on FDA labeling in defense against claims of inadequate warnings.
- Manufacturer Liability: Shire’s successful defense demonstrates that adherence to regulatory standards can limit liability, shifting focus to federal approval processes rather than state law claims.
Future Implications
- Regulatory Compliance: Pharmaceutical companies must ensure labels align with FDA standards to strengthen preemption defenses.
- Litigation Strategy: Plaintiffs may focus on post-market data and side effect disclosures that emerge after FDA approval.
- Preemption Trends: Courts will likely continue favoring preemption where federal regulations provide a comprehensive safety framework.
Key Takeaways
- Federal preemption remains a significant hurdle for drug liability claims where FDA-approved labeling is the primary defense.
- Courts favor federal regulatory standards over state-law claims in pharmaceutical litigation.
- Successful defense depends on demonstrating that labeling complies with FDA standards at the time of the claim.
FAQs
1. Does FDA approval of a drug label eliminate liability for manufacturers?
Yes, courts often find that federal law preempts state claims if labels are consistent with FDA-approved information.
2. What role does post-market data play in these cases?
Post-market adverse event data can influence the court's view if it suggests the product's risks were underreported or not properly disclosed.
3. Can plaintiffs bypass federal preemption?
Plaintiffs may argue that claims are based on state law duties outside of labeling, but courts often find these claims preempted if they conflict with federal standards.
4. How has Shire’s defense strategy affected other similar cases?
It has established a legal precedent encouraging reliance on FDA approval as a primary shield in pharmaceutical litigation.
5. What are the implications for future drug manufacturers regarding labeling?
Manufacturers should maintain FDA compliance and document updates, as this significantly influences liability and defense strategies.
Sources:
- Peluso v. Shire U.S., Inc., 2:15-cv-07225, U.S. District Court for the Central District of California.
- U.S. Food and Drug Administration. (2022). Labeling & Labeling Compliance. Retrieved from https://www.fda.gov
- Bloomberg Law. (2022). Pharmaceutical Litigation and Federal Preemption. Retrieved from https://www.bloomberglaw.com
